Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options

References

• International Diabetes Federation2013IDF Atlas Available from: http://www.idf.org/diabetesatlasAccessed July 10, 2014
   Google Scholar
• Centers for Disease Control and Prevention2014National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014 Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdfAccessed July 16, 2014
   Google Scholar
• RowleyWRBezoldCCreating public awareness: state 2025 diabetes forecastsPopul Health Manag20121519420022283662
   PubMed Web of Science ®Google Scholar
• DeFronzoRABanting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusDiabetes20095877379519336687
   PubMed Web of Science ®Google Scholar
• FonsecaVADefining and characterizing the progression of type 2 diabetesDiabetes Care200932S151S15619875543
   PubMed Web of Science ®Google Scholar
• WarramJHMartinBCKrolewskiASSoeldnerJSKahnCRSlow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parentsAnn Intern Med19901139099152240915
   PubMed Web of Science ®Google Scholar
• MillsGWAveryPJMcCarthyMIHeritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetesDiabetologia20044773273815298351
   PubMed Web of Science ®Google Scholar
• GrantRWMooreAFFlorezJCGenetic architecture of type 2 diabetes: recent progress and clinical implicationsDiabetes Care2009321107111419460916
   PubMed Web of Science ®Google Scholar
• KahnSEClinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetesJ Clin Endocrinol Metab2001864047405811549624
   PubMed Web of Science ®Google Scholar
• ChangAMHalterJBAging and insulin secretionAm J Physiol Endocrinol Metab2003284E7E1212485807
   PubMed Web of Science ®Google Scholar
• HuFBGlobalization of diabetes: the role of diet, lifestyle, and genesDiabetes Care2011341249125721617109
   PubMed Web of Science ®Google Scholar
• PoitoutVRobertsonRPMinireview: secondary beta-cell failure in type 2 diabetes – a convergence of glucotoxicity and lipotoxicityEndocrinology200214333934211796484
   PubMed Web of Science ®Google Scholar
• CarpentierAMittelmanSDBergmanRNGiaccaALewisGFProlonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetesDiabetes20004939940810868961
   PubMed Web of Science ®Google Scholar
• KashyapSBelfortRGastaldelliAA sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetesDiabetes2003522461247414514628
   PubMed Web of Science ®Google Scholar
• UngerRHZhouYTLipotoxicity of beta-cells in obesity and in other causes of fatty acid spilloverDiabetes200150S118S12111272168
   PubMed Web of Science ®Google Scholar
• GerichJEMeyerCWoerleHJStumvollMRenal gluconeogenesis: its importance in human glucose homeostasisDiabetes Care20012438239111213896
   PubMed Web of Science ®Google Scholar
• HeitJALeibsonCLAshraniAAPettersonTMBaileyKRMeltonLJ3rdIs diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based case-control studyArterioscler Thromb Vasc Biol2009291399140519542020
   PubMed Web of Science ®Google Scholar
• ShahPVellaABasuABasuRSchwenkWFRizzaRALack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitusJ Clin Endocrinol Metab2000854053405911095432
   PubMed Web of Science ®Google Scholar
• HuangSCzechMPThe GLUT4 glucose transporterCell Metab2007523725217403369
   PubMed Web of Science ®Google Scholar
• HermanMAKahnBBGlucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmonyJ Clin Invest20061161767177516823474
   PubMed Web of Science ®Google Scholar
• CusiKMaezonoKOsmanAInsulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscleJ Clin Invest200010531132010675357
   PubMed Web of Science ®Google Scholar
• BaysHMandarinoLDeFronzoRARole of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approachJ Clin Endocrinol Metab20048946347814764748
   PubMed Web of Science ®Google Scholar
• SaelyCHGeigerKDrexelHBrown versus white adipose tissue: a mini-reviewGerontology201258152321135534
   PubMed Web of Science ®Google Scholar
• CypessAMLehmanSWilliamsGIdentification and importance of brown adipose tissue in adult humansN Engl J Med20093601509151719357406
   PubMed Web of Science ®Google Scholar
• SaitoMOkamatsu-OguraYMatsushitaMHigh incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposityDiabetes2009581526153119401428
   PubMed Web of Science ®Google Scholar
• van Marken LichtenbeltWDVanhommerigJWSmuldersNMCold-activated brown adipose tissue in healthy menN Engl J Med20093601500150819357405
   PubMed Web of Science ®Google Scholar
• VirtanenKALidellMEOravaJFunctional brown adipose tissue in healthy adultsN Engl J Med20093601518152519357407
   PubMed Web of Science ®Google Scholar
• OuelletVLabbeSMBlondinDPBrown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humansJ Clin Invest201212254555222269323
   PubMed Web of Science ®Google Scholar
• BostromPWuJJedrychowskiMPA PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesisNature201248146346822237023
   PubMed Web of Science ®Google Scholar
• PagottoUWhere does insulin resistance start? The brainDiabetes Care200932S174S17719875547
   PubMed Web of Science ®Google Scholar
• TschritterOPreisslHHennigeAMThe cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic studyProc Natl Acad Sci U S A2006103121031210816877540
   PubMed Web of Science ®Google Scholar
• RothJDMaierHChenSRolandBLImplications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applicationsArch Neurol20096630631019273748
   PubMedGoogle Scholar
• WoodsSCLutzTAGearyNLanghansWPancreatic signals controlling food intake; insulin, glucagon and amylinPhilos Trans R Soc Lond B Biol Sci20063611219123516815800
   PubMed Web of Science ®Google Scholar
• FriedmanJMLeptin at 14 y of age: an ongoing storyAm J Clin Nutr200989973S979S19190071
   PubMed Web of Science ®Google Scholar
• ConsidineRVSinhaMKHeimanMLSerum immunoreactive-leptin concentrations in normal-weight and obese humansN Engl J Med19963342922958532024
   PubMed Web of Science ®Google Scholar
• MortonGJSchwartzMWLeptin and the central nervous system control of glucose metabolismPhysiol Rev20119138941121527729
   PubMed Web of Science ®Google Scholar
• FarooqiISO’RahillySLeptin: a pivotal regulator of human energy homeostasisAm J Clin Nutr200989980S984S19211814
   PubMed Web of Science ®Google Scholar
• GermanJPWisseBEThalerJPLeptin deficiency causes insulin resistance induced by uncontrolled diabetesDiabetes2010591626163420424233
   PubMed Web of Science ®Google Scholar
• MittendorferBHorowitzJFDePaoliAMMcCamishMAPattersonBWKleinSRecombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetesDiabetes2011601474147721411512
   PubMed Web of Science ®Google Scholar
• HeppnerKMTongJMechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actionsEur J Endocrinol2014171R21R3224714083
   PubMed Web of Science ®Google Scholar
• DateYNakazatoMHashiguchiSGhrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretionDiabetes20025112412911756331
   PubMed Web of Science ®Google Scholar
• VolanteMAlliaEGugliottaPExpression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumorsJ Clin Endocrinol Metab2002871300130811889202
   PubMed Web of Science ®Google Scholar
• BroglioFArvatEBensoAGhrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humansJ Clin Endocrinol Metab2001865083508611600590
   PubMed Web of Science ®Google Scholar
• TongJPrigeonRLDavisHWGhrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humansDiabetes2010592145215120584998
   PubMed Web of Science ®Google Scholar
• GarinMCBurnsCMKaulSCappolaARClinical review: the human experience with ghrelin administrationJ Clin Endocrinol Metab2013981826183723533240
   PubMed Web of Science ®Google Scholar
• PöykköSMKellokoskiEHörkköSKaumaHKesäniemiYAUkkolaOLow plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetesDiabetes2003522546255314514639
   PubMed Web of Science ®Google Scholar
• FreemanJSRole of the incretin pathway in the pathogenesis of type 2 diabetes mellitusCleve Clin J Med200976S12S1919952298
   PubMedGoogle Scholar
• NauckMABallerBMeierJJGastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetesDiabetes200453S190S19615561910
   PubMed Web of Science ®Google Scholar
• DunganKBuseJBGlucagon-like peptide 1–based therapies for type 2 diabetes: a focus on exenatideClin Diabetes2005235662
   Google Scholar
• BakrisGLFonsecaVASharmaKWrightEMRenal sodium-glucose transport: role in diabetes mellitus and potential clinical implicationsKidney Int2009751272127719357717
   PubMed Web of Science ®Google Scholar
• FerranniniESodium-glucose transporter-2 inhibition as an antidiabetic therapyNephrol Dial Transplant2010252041204320466683
   PubMed Web of Science ®Google Scholar
• DeFronzoRAHompeschMKasichayanulaSCharacterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetesDiabetes Care2013363169317623735727
   PubMed Web of Science ®Google Scholar
• StumvollMChintalapudiUPerrielloGWelleSGutierrezOGerichJUptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrineJ Clin Invest199596252825337593645
   PubMed Web of Science ®Google Scholar
• MeyerCStumvollMNadkarniVDostouJMitrakouAGerichJAbnormal renal and hepatic glucose metabolism in type 2 diabetes mellitusJ Clin Invest19981026196249691098
   PubMed Web of Science ®Google Scholar
• FoxCSCoadySSorliePDIncreasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart StudyCirculation20071151544155017353438
   PubMed Web of Science ®Google Scholar
• CoreshJSelvinEStevensLAPrevalence of chronic kidney disease in the United StatesJAMA20072982038204717986697
   PubMed Web of Science ®Google Scholar
• FoleyRNCollinsAJEnd-stage renal disease in the United States: an update from the United States Renal Data SystemJ Am Soc Nephrol2007182644264817656472
   PubMed Web of Science ®Google Scholar
• OhkuboYKishikawaHArakiEIntensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Res Clin Pract1995281031177587918
   PubMed Web of Science ®Google Scholar
• No authors listedEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) GroupLancet1998a3528548659742977
   PubMed Web of Science ®Google Scholar
• No authors listedIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet1998b3528378539742976
   PubMed Web of Science ®Google Scholar
• GaedePLund-AndersenHParvingHHPedersenOEffect of a multifactorial intervention on mortality in type 2 diabetesN Engl J Med200835858059118256393
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationApproaches to glycemic treatment. Sec 7. In Standards of medical care in diabetes – 2015Diabetes Care201538Suppl 1S41S4825537707
   PubMed Web of Science ®Google Scholar
• GarberAJAbrahamsonMJBarzilayJIAmerican Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement – executive summaryEndocr Pract20131953655723816937
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBAmerican Diabetes AssociationEuropean Association for Study of DiabetesMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care20093219320318945920
   PubMed Web of Science ®Google Scholar
• KnowlerWCBarrett-ConnorEFowlerSEDiabetes Prevention Program Research GroupReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med200234639340311832527
   PubMed Web of Science ®Google Scholar
• CheungBMOngKLChernySSShamPCTsoAWLamKSDiabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006Am J Med200912244345319375554
   PubMed Web of Science ®Google Scholar
• SchmittdielJAUratsuCSKarterAJWhy don’t diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensificationJ Gen Intern Med20082358859418317847
   PubMed Web of Science ®Google Scholar
• VallonVPlattKACunardRSGLT2 mediates glucose reabsorption in the early proximal tubuleJ Am Soc Nephrol20112210411220616166
   PubMed Web of Science ®Google Scholar
• ListJFWhaleyJMGlucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humansKidney Int201179S20S27
   Web of Science ®Google Scholar
• GerichJERole of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implicationsDiabet Med20102713614220546255
   PubMed Web of Science ®Google Scholar
• BolinderJLjunggrenOKullbergJEffects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metforminJ Clin Endocrinol Metab2012971020103122238392
   PubMed Web of Science ®Google Scholar
• BaileyCJSGLT2 inhibitors: glucuretic treatment for type 2 diabetesBr J Diabetes Vasc Dis201010193199
   Google Scholar
• Abdul-GhaniMANortonLDefronzoRARole of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetesEndocr Rev20113251553121606218
   PubMed Web of Science ®Google Scholar
• ChaoECHenryRRSGLT2 inhibition – a novel strategy for diabetes treatmentNat Rev Drug Discov2010955155920508640
   PubMed Web of Science ®Google Scholar
• FerranniniERamosSJSalsaliATangWListJFDapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trialDiabetes Care2010332217222420566676
   PubMed Web of Science ®Google Scholar
• BaileyCJGrossJLPietersABastienAListJFEffect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialLancet20103752223223320609968
   PubMed Web of Science ®Google Scholar
• NauckMADel PratoSMeierJJDapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trialDiabetes Care2011342015202221816980
   PubMed Web of Science ®Google Scholar
• StrojekKYoonKHHrubaVElzeMLangkildeAMParikhSEffect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trialDiabetes Obes Metab20111392893821672123
   PubMed Web of Science ®Google Scholar
• RosenstockJVicoMWeiLSalsaliAListJFEffects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapyDiabetes Care2012351473147822446170
   PubMed Web of Science ®Google Scholar
• JabbourSHardyESuggJEParikhSDapagliflozin as add-on therapy to sitagliptin with or without metformin: a randomized, double-blind, placebo-controlled studyDiabetes201261A275
   Web of Science ®Google Scholar
• WildingJPHWooVSolerNGDapagliflozin 006 Study GroupLong-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulinAnn Intern Med2012b15640541522431673
   PubMed Web of Science ®Google Scholar
• HenryRRMurrayAVMarmolejoMHHennickenDPtaszynskaAListJFDapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trialInt J Clin Pract20126644645622413962
   PubMed Web of Science ®Google Scholar
• KohanDEFiorettoPTangWListJFLong-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic controlKidney Int20148596297124067431
   PubMed Web of Science ®Google Scholar
• Farxiga® (dapagliflozin). 2014Full Prescribing InformationPrinceton NJ, USABristol-Myers SquibbWilmington, DE, USAAstraZeneca2014
   Google Scholar
• WildingJPWooVRohwedderKSuggJParikhSDapagliflozin 006 Study GroupDapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over two yearsDiabetes Obes Metab20141612413623911013
   PubMed Web of Science ®Google Scholar
• BaileyCJGrossJLHennickenDIqbalNMansfieldTAListJFDapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trialBMC Med2013114323425012
   PubMed Web of Science ®Google Scholar
• BolinderJLjunggrenOJohanssonLDapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metforminDiabetes Obes Metab20141615916923906445
   PubMed Web of Science ®Google Scholar
• Lambers HeerspinkHJde ZeeuwDWieLLeslieBListJDapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetesDiabetes Obes Metab20131585386223668478
   PubMed Web of Science ®Google Scholar
• PtaszynskaAChalamandarisASuggJEJohnssonKMParikhSListJLEffect of dapagliflozin on renal functionDiabetes201261A283
   Web of Science ®Google Scholar
• JohnssonKMPtaszynskaASchmitzBSuggJParikhSJListJFVulvovaginitis and balanitis in patients with diabetes treated with dapagliflozinJ Diabetes Complications2013b2747948423806570
   PubMed Web of Science ®Google Scholar
• JohnssonKMPtaszynskaASchmitzBSuggJParikhSJListJFUrinary tract infections in patients with diabetes treated with dapagliflozinJ Diabetes Complications2013a2747347823849632
   PubMed Web of Science ®Google Scholar
• StenlofKCefaluWTKimKAEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes Obes Metab20131537238223279307
   PubMed Web of Science ®Google Scholar
• CefaluWTLeiterLAYoonKHEfficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialLancet201338294195023850055
   PubMed Web of Science ®Google Scholar
• WildingJPMathieuCVercruysseFCanagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes (T2D) inadequately controlled with metformin (MET) and sulfonylurea (SU)Diabetes2012a61A262
   Web of Science ®Google Scholar
• SchernthanerGGrossJLRosenstockJCanagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trialDiabetes Care2013362508251523564919
   PubMed Web of Science ®Google Scholar
• YaleJFBakrisGCariouBEfficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes Obes Metab20131546347323464594
   PubMed Web of Science ®Google Scholar
• RosenstockJPolodoriDZhaoYCanagliflozin, an inhibitor of sodium glucose co-transporter 2, improves glycaemic control, lowers body weight, and improves beta cell function in subjects with type 2 diabetes on background metforminDiabetologia2010b53S351
   Web of Science ®Google Scholar
• WrightEMLooDDHirayamaBABiology of human sodium glucose transportersPhysiol Rev20119173379421527736
   PubMed Web of Science ®Google Scholar
• PolidoriDShaSMudaliarSCanagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled studyDiabetes Care2013362154216123412078
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationEndocrinologic and Metabolic Drugs Advisory Committee1102013 Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm331504.htmAccessed July 16, 2014
   Google Scholar
• SinclairABodeBHarrisSEfficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesBMC Endocr Disord2014143724742013
   PubMed Web of Science ®Google Scholar
• Invokana® (canagliflozin)Full Prescribing InformationTitusville, NJ, USAJanssen Pharmaceuticals2013
   Google Scholar
• FerranniniESemanLSeewaldt-BeckerEHantelSPinnettiSWoerleHJA Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetesDiabetes Obes Metab2013a1572172823398530
   PubMed Web of Science ®Google Scholar
• RosenstockJSemanLJJelaskaAEfficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemiaDiabetes Obes Metab2013151154116023906374
   PubMed Web of Science ®Google Scholar
• KovacsCSSeshiahVSwallowREMPA-REG PIO™ trial investigatorsEmpagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trialDiabetes Obes Metab20141614715823906415
   PubMed Web of Science ®Google Scholar
• HaringHUMerkerLSeewaldt-BeckerEEMPA-REG METSU Trial InvestigatorsEmpagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialDiabetes Care2013363396340423963895
   PubMed Web of Science ®Google Scholar
• WoerleHJFerranniniEBerkASafety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetesDiabetes201261LB13
   Web of Science ®Google Scholar
• FonsecaVAFerranniniEWildingJPActive- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitusJ Diabetes Complications20132726827323276620
   PubMed Web of Science ®Google Scholar
• WildingJPFerranniniEFonsecaVAWilpshaarWDhanjalPHouzerAEfficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding studyDiabetes Obes Metab2013a1540340923163880
   PubMed Web of Science ®Google Scholar
• FerranniniEVeltkampSASmuldersRAKadokuraTRenal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetesDiabetes Care2013b361260126523359360
   PubMed Web of Science ®Google Scholar
• SeinoYSasakiTFukatsuASamukawaYSakaiSWatanabeTLuseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitusDiabetes201261A266
   Web of Science ®Google Scholar
• KadowakiTIkedaSTakanoYTofogliflozin, a novel and selective SGLT2 inhibitor improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled on stable metformin or diet and excercise aloneDiabetes201261A22
   Web of Science ®Google Scholar
• MandemaJSweeneyKTerraSSahasrabudheVModel-based meta-analysis of the HbA1c lowering effect of PF-04971729, a sodium glucose co-transporter-2 inhibitor (SGLT2i), in comparison with other SGLT2i and anti-diabetic agents (ADA)Diabetes201261A260
   Web of Science ®Google Scholar
• ZambrowiczBFreimanJBrownPMLX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trialClin Pharmacol Ther20129215816922739142
   PubMed Web of Science ®Google Scholar
• OvertonHAFyfeMCReynetCGPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesityBr J Pharmacol2008153S76S8118037923
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineA study in type 2 diabetics of single and multiple doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics Available from: http://clinicaltrials.gov/ct2/show/NCT01119846?term=gsk1292263&rank=1Accessed July 16, 2014
   Google Scholar
• CymaBay Therapeutics IncStudy to evaluate the efficacy, safety, tolerability, and pharmacokinetics of MBX-2982 administered daily for 4 weeks as monotherapy in patients with type 2 diabetes Available from: http://clinicaltrials.gov/ct2/show/NCT01035879?term=mbx2982&rank=1Accessed July 16, 2014
   Google Scholar
• KatzLBGambaleJJRothenbergPLEffects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetesDiabetes Obes Metab20121470971622340428
   PubMed Web of Science ®Google Scholar
• KebedeMAAlquierTLatourMGPoitoutVLipid receptors and islet function: therapeutic implications?Diabetes Obes Metab200911102019817784
   PubMed Web of Science ®Google Scholar
• BurantCFViswanathanPMarcinakJTAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trialLancet20123791403141122374408
   PubMed Web of Science ®Google Scholar
• CooperMSStewartPM11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammationJ Clin Endocrinol Metab2009944645465419837912
   PubMed Web of Science ®Google Scholar
• RosenstockJBanarerSFonsecaVAINCB13739-202 Principal InvestigatorsThe 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapyDiabetes Care2010a331516152220413513
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBAmerican Diabetes Association (ADA)European Association for the Study of Diabetes (EASD)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care2012351364137922517736
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care20153814014925538310
   PubMed Web of Science ®Google Scholar
• BlondeLCurrent antihyperglycemic treatment strategies for patients with type 2 diabetes mellitusCleve Clin J Med200976Suppl 5S4S1119952303
   PubMedGoogle Scholar
• ZangenehFKudvaYCBasuAInsulin sensitizersMayo Clin Proc20037847147912683699
   PubMed Web of Science ®Google Scholar
• Welchol® (colesevelam HCl)Full Prescribing InformationParsippany, NJ, USADaiichi Sankyo, Inc2010
   Google Scholar
• Cycloset® (bromocriptine mesylate)Full Prescribing InformationTiverton, RIVeroScience, LLC2010
   Google Scholar